Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Weber

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research RoundtableGill Farrar, Christopher J Weber, Gil D Rabinovici
Clinical Pediatrics|November 29, 2017
Injuries Depicted in Sport-Related FilmsRobert P Olympia, Hannah Wakefield, Bryan Wakefield, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 10, 2022
Current understanding of AD pathophysiology and impact of amyloid beta-targeted treatments on biomarkers and clinical endpointsRonald C Petersen, Ana Graf, Maria C Carrillo, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2022
Current understanding of AD pathophysiology and impact of amyloid-beta targeted treatments on biomarkers and clinical endpointsRonald C Petersen, Ana Graf, Maria C Carrillo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 10, 2020
Clinical meaningfulness addressed at Alzheimer's Association Research RoundtableDorene M Rentz, Alette M Wessels, Lisa J Bain, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2024
ADNI Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion (DE&I) Working Group: A new collaboration that crosses boundaries for industry, academia, and under-represented patientsRuth Croney, Emil Fristed, Donna Masterman, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Alzheimer's disease drug development in an evolving therapeutic landscapeStacie Weninger, Michael C Irizarry, Adam S Fleisher, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 12, 2025
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meetingRonald C Petersen, Ana Graf, Chris Brady, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 7, 2023
Expectations and clinical meaningfulness of randomized controlled trialsRonald C Petersen, Paul S Aisen, J Scott Andrews, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 29, 2023
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerationsRonald C Petersen, Ana Graf, Chris Brady, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research RoundtableGill Farrar, Christopher J Weber, Gil D Rabinovici
Clinical Pediatrics|November 29, 2017
Injuries Depicted in Sport-Related FilmsRobert P Olympia, Hannah Wakefield, Bryan Wakefield, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 10, 2022
Current understanding of AD pathophysiology and impact of amyloid beta-targeted treatments on biomarkers and clinical endpointsRonald C Petersen, Ana Graf, Maria C Carrillo, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2022
Current understanding of AD pathophysiology and impact of amyloid-beta targeted treatments on biomarkers and clinical endpointsRonald C Petersen, Ana Graf, Maria C Carrillo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 10, 2020
Clinical meaningfulness addressed at Alzheimer's Association Research RoundtableDorene M Rentz, Alette M Wessels, Lisa J Bain, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2024
ADNI Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion (DE&I) Working Group: A new collaboration that crosses boundaries for industry, academia, and under-represented patientsRuth Croney, Emil Fristed, Donna Masterman, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Alzheimer's disease drug development in an evolving therapeutic landscapeStacie Weninger, Michael C Irizarry, Adam S Fleisher, et al.
Alzheimer'S & Dementia (New York, N. Y.)|February 12, 2025
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meetingRonald C Petersen, Ana Graf, Chris Brady, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 7, 2023
Expectations and clinical meaningfulness of randomized controlled trialsRonald C Petersen, Paul S Aisen, J Scott Andrews, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 29, 2023
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerationsRonald C Petersen, Ana Graf, Chris Brady, et al.
Pageof 4